Luqa Pharma To Commercialize BMG Pharma’s Products In China

Chinese pharma Luqa Pharmaceuticals will commercialize BMG Pharma’s products in China and Hong Kong.

AsianScientist (Jul. 22, 2013) – Italian pharma BMG Pharma S.r.l and Chinese pharma Luqa Pharmaceuticals announced this month a long-term partnership for the commercialization of BMG’s products in China and Hong Kong.

Luqa Pharmaceuticals is a China-based, product focused company that acquires, develops and commercializes innovative healthcare products suited to the needs of China. Under the terms of this agreement, Luqa will exclusively register and commercialize BMG’s highly innovative dermatology, oral care and Cancer Support Therapy products.

The agreement will enable Luqa to rapidly expand its dermatology offering and enter the attractive oral care and supportive care market of China. The partnership covers IaluXid, a unique, non-antibiotic, combination gel formulation treating skin infections; GelX and GelX Xero, supportive care for preventing and treating oral mucositis and xerostomia; and Aftacure, for treating aphthous ulcers and mouth lesions. Luqa expects to launch this family of products directly from late 2015 onwards.

“We are pleased to enter into a partnership with Luqa Pharmaceuticals, a company with whom we share the vision and values. BMG’s proven innovation capabilities complements Luqa’s deep understanding of the evolving needs in China’s healthcare market”, said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l.

——

Source: BMG Pharma Srl.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist